SPONSORED CONTENT
Let’s be honest. 340B compliance is demanding. It takes time, coordination, and precision. After more than a decade working in 340B compliance and auditing, I’ve learned it always comes back to one thing: the data.
Where does the data come from? How accurate is it? How quickly can we analyze it? Whose responsibility is it to review? And who else should be part of that conversation? These are the first questions any covered entity must answer.
If we only think about 340B as a compliance requirement, we miss what it can unlock: turning compliance into strategy.
My career has followed a similar shift. I started as a pharmacy technician in a large retail chain. It taught me a lot, but I wanted to do more. When I discovered 340B, it fundamentally changed how I understood healthcare. Years later, when The Craneware Group formed, I was introduced to the broader world of revenue intelligence. It opened my eyes to how much healthcare organizations navigate behind the scenes to care for their communities.
And now, I’m seeing that same shift happening across the hospitals I work with. Leaders are starting to ask:
- How can our 340B data support more than audits?
- Where are margins eroding?
- Which medications are driving unnecessary costs?
- How can we make better decisions without compromising care?
At the same time, more states are introducing financial reporting and transparency requirements, placing even greater pressure on covered entities to not only comply but optimize.
Simply staying compliant is no longer enough. Organizations are looking for ways to get ahead.
The same insights that support compliance can—and should—drive broader strategic conversations. When we work with pharmacy leaders, it’s not only about reviewing reports, but also about uncovering trends that inform smarter purchasing decisions, stronger payor strategies, and more effective negotiations with manufacturers and wholesalers.
When you know where your opportunities are, every conversation becomes more valuable.
This is where the Trisus® Business of Pharmacy Suite comes in. It is a set of integrated tools designed to help surface the kind of insights that guide smarter contract decisions, support therapeutic substitutions, and make value-based care models feel more achievable.
These are more than dashboards. They are conversation starters.
And they are helping connect teams that haven’t always worked together. Pharmacy. Finance. Supply chain. Compliance. Each brings a different lens. But when everyone is looking at the same data, the conversation shifts. It stops being about what is required and starts focusing on what is possible.
That shift often starts with a simple question: Why is this happening?
A finance leader notices a drop in reimbursement. A pharmacy director revisits a formulary decision. Once that door opens, data becomes a tool for clarity. Not only for checking the compliance box, but for making better decisions across the board.
That is what excites me most about where 340B is headed. Not just technology or policies, but the potential to rethink how we use the information we already have.
When we stop thinking of 340B as something we must do and start seeing it as something we can build from, it becomes a foundation for real strategy.
Yes, compliance still matters. It always will. But it shouldn’t be the end of the conversation. For hospitals that want to stay strong in an uncertain future, 340B can be one of the most powerful tools in their corner if we let it.
If you are rethinking what 340B can do for your organization, discover how data-driven insights can unlock stronger strategies. Visit thecranewaregroup.com to learn more.
Brittany Duty is a Senior Solutions Engagement Executive at The Craneware Group. She can be reached at bduty@craneware.com
